GlassScriptPhysician profile
Faye Yin
NPI 1780879742
$6,848.16
in general payments reported to CMS, 2019-2025
54 companies · $3,963 in 2025
The $3,963 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $115 · 2021: $611 · 2022: $480 · 2023: $245 · 2024: $1,148 · 2025: $3,963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,921 · Consulting Fee: $400 · Education: $35.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,921.42 |
| Consulting Fee | $400.00 |
| Education | $35.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $892.44 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $446.08 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $413.18 | 2019-2025 | Opdivo, Reblozyl, Krazati |
| Janssen Biotech, INC. | $392.35 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Eisai INC. | $338.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $328.76 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Beone Medicines USA, INC. | $316.51 | 2025 | Tevimbra, Brukinsa |
| Pfizer INC. | $237.17 | 2021-2025 | |
| Incyte Corporation | $227.68 | 2020-2025 | Monjuvi, Zynyz, Jakafi |
| Celgene Corporation | $212.77 | 2023-2025 | Reblozyl |
| Genzyme Corporation | $198.58 | 2022-2025 | |
| Puma Biotechnology, INC. | $197.71 | 2024-2025 | |
| Daiichi Sankyo INC. | $183.30 | 2021-2025 | Enhertu |
| Bayer Healthcare Pharmaceuticals INC. | $172.38 | 2019-2025 | |
| Abbvie INC. | $171.53 | 2022-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $160.89 | 2022-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.22 | 2019-2023 | Ofev |
| Aveo Pharmaceuticals, INC. | $125.00 | 2024 | |
| Karyopharm Therapeutics INC. | $125.00 | 2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $125.00 | 2019 | |
| Array Biopharma INC | $123.54 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Janssen Pharmaceuticals, INC | $100.17 | 2021 | |
| Legend Biotech USA INC. | $100.00 | 2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $93.95 | 2024-2025 | Monoferric, Cosela |
| Genentech USA, INC. | $86.57 | 2020-2025 | Tecentriq, Polivy |
| Kite Pharma, INC. | $76.30 | 2025 | Yescarta |
| Glaxosmithkline, LLC. | $73.41 | 2025 | Ojjaara, Blenrep, Jemperli |
| Dendreon Pharmaceuticals LLC | $66.85 | 2025 | Provenge |
| Geron Corporation | $64.25 | 2024-2025 | Rytelo |
| Lilly USA, LLC | $63.17 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $55.41 | 2025 | Besremi |
| Seagen INC. | $44.98 | 2019-2022 | |
| Amgen INC. | $40.37 | 2019-2022 | |
| Astellas Pharma US INC | $35.11 | 2021-2025 | Vyloy |
| Blueprint Medicines Corporation | $31.76 | 2022-2025 | Ayvakit |
| Kyowa Kirin, INC. | $29.93 | 2025 | |
| Myriad Genetic Laboratories, INC. | $29.46 | 2021-2022 | |
| Beigene USA, INC. | $29.44 | 2021-2022 | |
| Epizyme, INC. | $27.86 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $26.08 | 2025 | Onivyde, Somatuline Depot |
| G1 Therapeutics, INC. | $24.39 | 2023 | Cosela |
| Dova Pharmaceuticals | $21.06 | 2021 | |
| Emd Serono, INC. | $20.17 | 2025 | |
| Ge Healthcare | $19.57 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.41 | 2025 | Ultomiris |
| Sumitomo Pharma America, INC. | $17.85 | 2025 | Orgovyx |
| Novocure INC. | $17.32 | 2024 | Optune Lua (Novottf-200t) |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Taiho Oncology, INC. | $15.70 | 2025 | |
| Azurity Pharmaceuticals, INC. | $15.04 | 2025 | Danziten |
| Tg Therapeutics, INC. | $14.80 | 2021 | |
| Myovant Sciences INC. | $14.52 | 2021 | |
| Jazz Pharmaceuticals INC. | $14.50 | 2024 | |
| Rigel Pharmaceuticals, INC. | $13.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faye Yin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.